Emcure Pharmaceuticals Share Price | Emcure Pharmaceuticals Stock Screener
EMCURE
Pharmaceuticals
Share Price NSE
₹1839.10
▼
-17.40 (-0.94%)
Share Price BSE
₹1837.10
▼
-17.50 (-0.94%)
As of July 3, 2026, the Emcure Pharmaceuticals share price (NSE: EMCURE) is ₹1,839.10 on NSE and ₹1,837.10 on BSE, down 0.94% from the previous close, with shares trading between ₹1,830.20 and ₹1,860.00, and a 52-week range of ₹1,243.10–₹1,880.20.
Analyse EMCURE share price data and track historical price performance.
Use the Emcure Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Emcure Pharmaceuticals Market Cap
₹34,821.49 Cr.
EMCURE P/E Ratio (TTM)
37.24
Emcure Pharmaceuticals P/B Ratio
7.08
EPS (TTM)
₹48.77
Dividend Yield
0.19%
Debt to Equity
0.45
EMCURE 52 Week High
₹1880.20
Emcure Pharmaceuticals 52 Week Low
₹1243.10
Operating Margin
19.00%
Profit Margin
9.82%
EMCURE Revenue (TTM)
₹2,484.00
EBITDA
₹494.00
Net Income
₹244.00
Total Assets
₹8,233.00
Total Equity
₹4,642.00
Emcure Pharmaceuticals Share Price Chart
Screen Emcure Pharmaceuticals share price with an interactive chart. Analyse EMCURE price trends and volatility across different timeframes.
Emcure Pharmaceuticals Company Profile - Fundamental Screener
Screen Emcure Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for EMCURE shares.
Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Berjis M Desai
ISIN
INE168P01015
Website
https://www.emcure.com
Emcure Pharmaceuticals Balance Sheet Screener
Screen EMCURE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 8,233 | 7,806 | 6,673 | 6,064 | 6,807 | 6,004 | 5,644 | 5,247 |
| Current Assets | 4,556 | 4,260 | 3,836 | 3,424 | 3,718 | 2,703 | 2,453 | 2,335 |
| Fixed Assets | 3,197 | 3,125 | 2,147 | 2,044 | 2,188 | 2,382 | 2,247 | 2,049 |
| Liabilities | ||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 923 | 1,474 | 1,004 | 985 | 1,031 | 1,100 | 1,201 | 1,157 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 4,642 | 3,122 | 2,650 | 2,114 | 2,368 | 1,984 | 1,900 | 1,755 |
| Share Capital | 190 | 181 | 181 | 181 | 181 | 181 | 181 | 181 |
| Reserves & Surplus | 4,257 | 2,771 | 2,320 | 1,807 | 2,092 | 1,731 | 1,654 | 1,520 |
Emcure Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Emcure Pharmaceuticals income statement and profit fundamentals.
Analyze EMCURE quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Emcure Pharmaceuticals share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,484 | 2,121 | 2,104 | 2,273 | 2,365 | 1,783 | 1,839 | 2,038 | 1,967 | 1,571 | 1,664 | 1,697 |
| Expenses | 1,990 | 1,724 | 1,687 | 1,794 | 1,909 | 1,460 | 1,479 | 1,621 | 1,608 | 1,261 | 1,337 | 1,381 |
| EBITDA | 494 | 397 | 417 | 479 | 456 | 323 | 360 | 417 | 359 | 311 | 327 | 316 |
| Operating Profit % | 19.00% | 19.00% | 20.00% | 21.00% | 19.00% | 18.00% | 19.00% | 19.00% | 18.00% | 19.00% | 20.00% | 17.00% |
| Depreciation | 106 | 97 | 100 | 105 | 105 | 91 | 94 | 97 | 97 | 67 | 70 | 84 |
| Interest | 46 | 39 | 27 | 33 | 38 | 66 | 59 | 46 | 32 | 52 | 59 | 61 |
| Profit Before Tax | 341 | 261 | 291 | 341 | 314 | 167 | 207 | 273 | 230 | 191 | 198 | 171 |
| Tax | 97 | 63 | 76 | 90 | 82 | 46 | 55 | 72 | 74 | 50 | 52 | 51 |
| Net Profit | 244 | 197 | 215 | 251 | 231 | 121 | 153 | 202 | 156 | 141 | 146 | 120 |
| EPS | 12.84 | 9.97 | 10.92 | 12.85 | 12.16 | 6.36 | 7.95 | 10.23 | 8.12 | 7.21 | 7.70 | 6.27 |
Emcure Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen EMCURE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | 852 | 1,097 | 747 | 768 | 704 | 500 | 444 |
| Investing Activities | -96 | -715 | -468 | -575 | -257 | -168 | -409 |
| Financing Activities | -814 | -164 | -145 | -152 | -189 | -301 | -735 |
| Net Cash Flow | -58 | 219 | 134 | 42 | 259 | 32 | -700 |
Emcure Pharmaceuticals Shareholding Pattern Screener
See Emcure Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Emcure Pharmaceuticals promoter holding and ownership changes for EMCURE on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Jul | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 77.87% | 77.92% | 77.91% | 77.88% | 77.87% | 78.08% | 78.08% | 77.94% |
| FII Holding | 3.35% | 3.07% | 2.86% | 3.29% | 3.59% | 1.76% | 2.91% | 3.05% |
| DII Holding | 6.10% | 3.44% | 2.84% | 4.37% | 6.10% | 3.34% | 3.96% | 3.87% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.46% | 5.51% | 5.95% | 6.24% | 6.46% | 7.73% | 5.00% | 5.14% |
| Other Holding | 6.22% | 10.06% | 10.44% | 8.22% | 5.98% | 9.10% | 10.04% | 10.00% |
| Shareholder Count | 122,189 | 139,671 | 133,549 | 126,169 | 118,863 | 498,006 | 152,914 | 143,449 |
Emcure Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Emcure Pharmaceuticals dividend history with payout and yield data.
View Emcure Pharmaceuticals dividend details including ex-dates and amounts for EMCURE stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹3.00 | 0.19% |
| 2024-March | ₹2.00 | 0.19% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Emcure Pharmaceuticals Stock Index Membership
See which indices include Emcure Pharmaceuticals stock.
Check EMCURE index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX BSEIPO
BSE INDEX MIDCAP
NIFTY 500
NIFTY IPO
NIFTY MIDSML 400
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 MULTICAP
Emcure Pharmaceuticals Market Events Screener - Corporate Actions
Get Emcure Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Emcure Pharmaceuticals stock events that may affect EMCURE share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-05 | 2026-05-05 | Quarterly Result Announcement | NA | 9.10% |
| 2026-02-04 | 2026-02-04 | Quarterly Result Announcement | NA | -3.35% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 8.24% |
| 2025-08-28 | 2025-08-28 | Annual General Meeting | NA | 4.29% |
| 2025-08-14 | 2025-08-14 | Dividend | ₹ 3.00 /share | 35.41% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | 1.12% |
| 2025-05-22 | 2025-05-22 | Quarterly Result Announcement | NA | 3.59% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | -7.13% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 2.69% |
Emcure Pharmaceuticals Competitors Screener - Peer Comparison
Screen EMCURE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 446,876 | 39.04 | 58,220 | 6.38% | 11,565 | 60.32 |
| Divis Laboratories | 174,652 | 67.84 | 10,560 | 8.73% | 2,520 | 44.73 |
| Torrent Pharmaceuticals | 156,365 | 73.76 | 13,886 | 20.34% | 2,138 | 62.27 |
| Cipla | 118,382 | 30.41 | 29,045 | 2.24% | 3,870 | 69.96 |
| Dr Reddys Laboratories | 113,273 | 27.63 | 33,593 | -0.44% | 3,998 | 66.21 |
| Zydus Life Science | 111,954 | 22.03 | 26,720 | 13.65% | 5,242 | 62.64 |
| Lupin | 110,605 | 20.55 | 27,488 | 19.98% | 5,345 | 68.05 |
| Mankind Pharma | 105,132 | 52.96 | 14,278 | 12.03% | 1,750 | 64.79 |
| Aurobindo Pharma | 90,835 | 25.68 | 33,385 | 3.21% | 3,376 | 69.05 |
| Laurus Labs | 81,918 | 91.20 | 6,868 | 22.01% | 890 | 72.35 |
Emcure Pharmaceuticals Company Announcements - News Screener
Screen EMCURE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Change in Management | - | |
| 2026-07-04 | Closure of Trading Window | - |
| 2026-06-19 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-06-12 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-05-27 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-16 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - US FDA Inspection At Our Formulations Facility Located At Sanand Ahmedabad Gujarat India. | - |
| 2026-05-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-08 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating | - |
| 2026-05-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-05 | Corporate Action-Board approves Dividend | - |
| 2026-05-05 | Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31 2026 | - |